News und Analysen
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company’s Biologics License Application (BLA) for elranatamab, an
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV)
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
Pfizer (NYSE: PFE) announced today positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI®
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
Pfizer Inc. (NYSE: PFE) today announced publication of results in The Lancet Neurology from the Phase 3 pivotal clinical trial of zavegepant, an investigational calcitonin gene-related peptide
Humana Foundation Announces New Strategy to Eliminate Barriers to Equitable Health and Healthcare
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 41 years, today announced a new strategy to advance health equity by eliminating unjust and unnecessary barriers in
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for CIBINQO® (abrocitinib), expanding
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Andy Schmeltz, SVP Commercial Strategy & Innovation, and Navin Katyal, U.S. Commercial &
Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance
Agilent Technologies Inc. (NYSE: A) today announced the release of new NovoExpress software that introduces integrated compliance tools for NovoCyte flow cytometer systems. The compliance-enabling
Humana and ChenMed Announce Five-Year Network Agreement
ChenMed, one of the largest senior-focused primary care providers in the United States, and leading health and well-being company Humana Inc. (NYSE: HUM) have signed a new five-year agreement
Humana Healthy Horizons to Support Maternal Health of Black Moms in Kentucky via Programs, Grants
Humana Healthy Horizons in Kentucky, Humana’s (NYSE: HUM) Kentucky Medicaid Plan, is pleased to announce that three local community-based organizations will receive grants totaling $120,000 from
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).
The fourth-quarter 2022 earnings presentation and
Agilent to Announce First-Quarter Fiscal Year 2023 Financial Results Feb. 28
Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2023 after the stock market closes on Tuesday, Feb. 28. The company will host a live webcast
Go365 by Humana Announces Winners of Fifth Annual National Step Challenge, Resulting in 7.1 Billion Steps Taken and One Million Meals* Donated to Feeding America®
Today, leading health and well-being company, Humana Inc. (NYSE: HUM), announced the winners** of its 2022 Go365® National Step Challenge – a health and wellness competition that focuses on
Karen Moran Named President of Humana Military
Humana Military, a wholly owned subsidiary of Humana Inc. (NYSE: HUM), announced today that it has appointed healthcare industry veteran Karen Moran to Senior Vice President, President of Humana
Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test
Agilent Technologies Inc. (NYSE: A) today announced an agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services. The alliance will enable
CenterWell Senior Primary Care Expands Personalized Primary Care to Charlotte, Opening 3 New Centers in 2023
CenterWell Senior Primary Care will open three new senior-focused primary care centers in Charlotte this year, marking the company’s debut in the city and giving seniors access to CenterWell’s
Agilent Included in Just Capital’s 2023 List of Most Just Companies
Agilent Technologies Inc. (NYSE: A) is ranked 35 among the top 100 Most JUST companies, the fifth year the company has been included in the annual list by Just Capital and CNBC. Agilent also earned
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries
Pfizer Inc. (NYSE: PFE) today announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has
Humana, Feeding America® Partner to Support Mobile Food Pantries
Leading health and wellness company Humana Inc. (NYSE: HUM) is helping to address food insecurity with a $625,000 grant to Feeding America, supporting mobile food pantries in nine states.
This
Agilent Authorizes $2 Billion Share Repurchase Program
Agilent Technologies Inc. (NYSE: A) today announced that its board of directors has approved a new share repurchase program. The 2023 program authorizes the purchase of up to $2 billion of the
Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
Agilent Technologies, Inc. (NYSE: A) today announced a partnership with Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, to develop multiplex-immunohistochemistry diagnostic
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for its 20-valent
Waters Corporation Recognized for its Award-winning Products, Outstanding Leadership, and ESG Progress
Waters Corporation (NYSE:WAT) announced awards and recognitions from multiple independent industry organizations throughout 2022, highlighting strength and momentum of the company’s product
Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 41st Annual J.P. Morgan